Abstract: Antibody-drug conjugates (ADCs), known as “precision missiles” for cancer treatment, can accurately target tumor cells without harming normal tissues. The core of this technology lies inconjugation technology— the method of linking cytotoxic drugs (the warhead) with antibodies (the navigation system). This article starts from the working principle of ADCs, breaking down three major categories … Read more
1. Clipping Filter Method 1. Method: Determine the maximum allowable deviation between two samples based on experience (denote as A) When a new value is detected, determine: a. If the difference between the current value and the previous value <= A, then the current value is validb. If the difference between the current value and … Read more
Name: Ying’en Biotech-B Code: 09606.HK Current Stock Price: HKD 331.2 (as of the close on 2025/11/13) Market Capitalization: HKD 29.243 billion Industry: Biotechnology (ADC Drug Development) As a significant player in the global antibody-drug conjugate (ADC) field, Ying’en Biotech has rapidly advanced its core products and international collaboration strategies, achieving a year-on-year revenue growth of … Read more
This is a further supplement and expansion of the original content, aimed at providing a more comprehensive understanding of the ADC + DMA automatic acquisition system in STM32, including its working principles, configuration details, and application techniques. 1. Overview of System Principles The ADC + DMA automatic acquisition system is an efficient data acquisition architecture … Read more
On the battlefield of precise cancer treatment, Antibody-Drug Conjugates (ADCs) act like a “biological missile,” leveraging their precise targeting capabilities and powerful lethality to become a cornerstone of tumor therapy. However, the journey of this “missile” within the body is exceptionally complex, and accurately tracking it and predicting its behavior has become the key to … Read more
Dear non-clinical colleagues, following our previous discussion on the reproductive and developmental toxicity of traditional drugs, this time we will briefly discuss how to evaluate “special drugs” — “Which components of ADCs, such as antibodies, linkers, or payloads, need to be assessed for reproductive toxicity?” “Will gene therapy viral vectors integrate into germ cells, and … Read more
This study was led by Professor Guo Jun and Professor Sheng Xi Nan from Peking University Cancer Hospital, and the results have been published in the prestigious international journal The New England Journal of Medicine, and presented at the European Society for Medical Oncology (ESMO) conference. Core Efficacy Data: Significant Extension of Survival This study … Read more
Recently, the biopharmaceutical sector seems to be reviving. Perhaps the BD departments of MNCs have returned from their summer breaks, reigniting the cross-ocean BD wave. On October 17, Hansoh Pharmaceutical announced a licensing collaboration with global oncology giant Roche for its CDH17 ADC new drug HS-20110. Roche will pay 80 million USD as an upfront … Read more
1) The prognosis for refractory/relapsed LBCL not suitable for curative treatment is poor. The success of CD20×CD3 TCE mosunetuzumab combined with CD79b ADC polatuzumab vedotin in Phase 3 has provided patients with a novel, fixed-cycle, outpatient therapy. (Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial)In … Read more
ADC/DAC chips, or analog-to-digital and digital-to-analog converters, are responsible for converting real-world analog signals, such as temperature, pressure, sound, fingerprints, or images, into a digital format that is easier to process. Conversely, DACs modulate digital signals into analog signals. ADCs and DACs serve as the bridge between the real world and the digital world, representing … Read more